The stock is likely to gap up significantly on this regulatory de-risking event. Traders should watch for potential capital raise announcements as the company prepares for BLA submission and confirmatory study costs. Key near-term catalysts: final Type B meeting minutes (expected within 30 days), BLA submission timing confirmation, and alignment on confirmatory study design.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 17 $48.16entry
- T+1 · 5mo ago −3.88%α −4.66% · $46.29
- T+5 · 5mo ago +1.43%α +2.47% · $48.85
- T+20 · 4mo ago −18.27%α −19.59% · $39.36
- T+60 · 2mo ago −7.58%α −10.73% · $44.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure announced that the FDA has agreed the 3-year analysis from the Phase I/II study of AMT-130 in Huntington's disease can serve as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in Q3 2026. This is a major regulatory milestone for a gene therapy targeting a currently untreatable neurodegenerative disease with no approved disease-modifying therapies, de-risking the path to market for a pivotal pipeline asset.
Key Facts
- FDA communicated during a Type B meeting that 3-year Phase I/II data are acceptable as primary basis for BLA for accelerated approval of AMT-130 in Huntington's disease.
- Company plans to submit the BLA in the third quarter of 2026.
- FDA seeks alignment on confirmatory study design prior to BLA submission, including consideration of a concurrent standard-of-care control instead of a sham procedure.
- AMT-130 has RMAT, Breakthrough Therapy, and Fast Track designations from the FDA.
- No approved therapies exist to delay onset or slow progression of Huntington's disease.
Financial Impact
FDA acceptance of Phase I/II data for BLA submission is a transformative regulatory catalyst for a pre-commercial biotech with a $1.7B market cap. Commercial opportunity in a ~75,000-patient addressable population with no approved disease-modifying therapies. Successful accelerated approval would unlock a multi-billion-dollar peak sales opportunity.
Risk Factors
- FDA could ultimately conclude data are insufficient to support BLA or accelerated approval after reviewing the complete application.
- Confirmatory study design alignment and execution delays could push timeline.
- Company may need to raise additional capital to fund BLA submission, manufacturing, and confirmatory study.
- Longer-term post-approval requirements could be costly or difficult to satisfy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-074853 |
| Document: tm2618105d1_ex99-1.htm | 0001104659-26-074853 |
| Document: 0001104659-26-074853-index-headers.html | 0001104659-26-074853 |
| Document: 0001104659-26-074853-index.html | 0001104659-26-074853 |
| Document: 0001104659-26-074853.txt | 0001104659-26-074853 |
Track record
38 reports on QURE
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers